1997
DOI: 10.1089/hyb.1997.16.381
|View full text |Cite
|
Sign up to set email alerts
|

Rapid Development of Affinity Matured Monoclonal Antibodies Using RIMMS

Abstract: Affinity matured murine monoclonal antibody producing cell lines can now be rapidly generated using a novel repetitive, multiple site immunization strategy designated RIMMS. RIMMS capitalizes on rapid hypermutation and affinity maturation events which occur in B cell populations localized within secondary lymphatic tissue early in response to antigenic challenges. A murine myeloma cell line, P3XBcl-2-13, stably transfected with Bcl-2, enhances the outgrowth of hybridomas following somatic fusion with immune ly… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
50
0

Year Published

2000
2000
2021
2021

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 77 publications
(50 citation statements)
references
References 45 publications
0
50
0
Order By: Relevance
“…The CPZ-1 protein was then cleaved from the GST fusion peptide by thrombin according to the recommendation from the manufacturer. A mouse anti-serum was raised against the purified CPZ-1 recombinant protein using the repetitive immunizations/multiple sites strategy (23,24). Each mouse received a total of 10 g of CPZ-1 emulsified in Ribi's adjuvant on days 0, 3, 6, 8, and 10.…”
Section: Methodsmentioning
confidence: 99%
“…The CPZ-1 protein was then cleaved from the GST fusion peptide by thrombin according to the recommendation from the manufacturer. A mouse anti-serum was raised against the purified CPZ-1 recombinant protein using the repetitive immunizations/multiple sites strategy (23,24). Each mouse received a total of 10 g of CPZ-1 emulsified in Ribi's adjuvant on days 0, 3, 6, 8, and 10.…”
Section: Methodsmentioning
confidence: 99%
“…All mutants are therefore significantly more active than the previously characterized pNO 2 Phe 86 mTNF-␣, which has only 2% of the activity of the wild-type protein in this assay. To determine the immunogenicity of these pNO 2 Phe mTNF-␣ mutants, 14 C57BL/6 mice were randomized into 5 groups and injected with these mutants, or WT mTNF-␣ by the RIMMS (repetitive immunization at multiple sites) protocol (14). An ELISA analysis revealed no correlation between mTNF-␣ activity in the NF B-luciferase reporter gene assay and the ability to induce an antibody response, ruling out a direct effect on the immune system.…”
Section: Extension To Mutations At Other Surface Sites Within Mtnf-␣mentioning
confidence: 99%
“…To determine the immunogenicity of the pNO 2 Phe mRBP4 mutants, 9 Bcl-2 transgenic mice were randomized into 3 groups and injected with pNO 2 Phe 43 mRBP4, pNO 2 Phe 108 mRBP4 and WT mRBP4 by the RIMMS protocol (14). According to ELISA analysis, mice immunized with either W T mRBP4 or pNO 2 Phe 108 mRBP4 had insignificant serum IgG titers against WT mRBP4 (Fig.…”
Section: Extension To Mutations At Other Surface Sites Within Mtnf-␣mentioning
confidence: 99%
“…To determine the immunogenicity of the pNO 2 Phe 86 mTNF-␣ mutant, 32 C57BL/6 mice were randomized into three groups and injected with pNO 2 Phe 86 mTNF-␣, WT mTNF-␣, and PBS buffer by using the RIMMS (repetitive immunization at multiple sites) protocol (25). To avoid adverse effects due to cytotoxicity of mTNF-␣, a dose of 5 g of mTNF-␣ per injection was used throughout this study (26).…”
Section: Expression and Characterization Of Mutant Mtnf-␣ Proteinsmentioning
confidence: 99%